Mike Auerbach

In today’s development landscape—particularly in oncology and non-opioid pain indications— "fit-for-purpose" early-phase formulations are disappearing. To meet accelerated timelines, developers must create commercially relevant, registration-ready products almost immediately after candidate selection. Join Nick Montalbano, a chemical engineer from Serán BioScience, for a high-impact webinar designed for busy professionals.

Liquid-filled capsules have moved from a niche dosage form to a mainstream option for delivering complex, poorly soluble and sensitive active pharmaceutical ingredients (APIs).1 Their evolution reflects advances in formulation science, precision filling technologies and a more rigorous regulatory focus on process understanding and control across the finished dosage form life cycle.2,3 As a result, liquid-filled capsules are no longer a specialized workaround but a technically sophisticated...

Advances in technologies, data and development strategies are reshaping how oral solid dosage (OSD) drugs are designed and manufactured, with a clear emphasis on lowering cost, shortening timelines, and improving quality and reliability across the life cycle.1 From ingredient sourcing and in silico modeling to continuous manufacturing and decentralized clinical trials, current thinking centers on building lean, integrated and data-rich OSD platforms that can adapt to market and regulatory...